The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include: the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-based leading provider of endpoint data solutions for clinical trials. The acquisition expands the segment’s portfolio with the addition of highly complementary clinical research offerings, enabling customers to gain critical insights from clinical data to improve decision-making, accelerate innovation and drive greater productivity. The goodwill recorded as a result of this business combination is not tax deductible.


(In millions)	Clario
Purchase price
Cash paid	$	5,811
Debt settled	3,180
Purchase price payable	115
Fair value of contingent consideration	113
Cash acquired	(117)
	$	9,102

Net assets acquired
Definite-lived intangible assets
Customer relationships	$	2,510
Product technology	844
Trade names	19
Backlog	423
Goodwill	5,945
Net other assets/(liabilities)	380
Contract liabilities	(375)
Deferred tax assets/(liabilities)	(645)
	$	9,102

The preliminary allocation of the purchase price for the acquisition of Clario is based on the estimates of the fair value of the purchase price and net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets, contract liabilities and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.

In 2026, the company also acquired, within the Analytical Instruments segment, two proteomics software companies including one in the U.S. and one in Germany, further strengthening our mass spectrometry and proteomics software capabilities.

The weighted-average amortization periods for definite-lived intangible assets acquired in 2026 are 20 years for customer relationships, 7 years for product technology, 3 years for trade names, and 6 years for backlog. The weighted-average amortization period for all definite-lived intangible assets acquired in 2026 is 15 years.

On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The business strengthens the segment’s bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and medical device manufacturing. The goodwill recorded as a result of this business combination is not tax deductible.


(In millions)	Filtration and separation business
Purchase price
Cash paid	$	3,939
Fair value of contingent consideration	(66)
Cash acquired	(9)
	$	3,865

Net assets acquired
Property, plant and equipment	$	468
Definite-lived intangible assets
Customer relationships	1,116
Product technology	388
Trade names	51
Goodwill	2,071
Net other assets/(liabilities)	148
Deferred tax assets/(liabilities)	(376)
	$	3,865

In addition, in 2025, the company acquired within the Laboratory Products and Biopharma Services segment, a sterile fill finishing and packaging facility to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity.

The weighted-average amortization periods for definite-lived intangible assets acquired in 2025 are 18 years for customer relationships, 19 years for product technology, and 15 years for trade names. The weighted-average amortization period for all definite-lived intangible assets acquired in 2025 is 18 years.

On August 12, 2026, the company sold its microbiology business to Astorg for approximately $1.07 billion, consisting of cash and a promissory note. The business was part of the Specialty Diagnostics segment. The sale of this business resulted in a pre-tax gain of $72 million, included in restructuring and other costs. Revenues in 2026, through the date of sale, and for the full year 2025 were $294 million and $476 million, respectively, net of retained sales through the company's healthcare market and research and safety market channel.

On September 4, 2026, the company entered into an agreement to sell a pharma services manufacturing facility along with customer contracts and employees from its Laboratory Products and Biopharma Services segment. The company recognized a held-for-sale loss of $244 million in the third quarter of 2026.